IP Library › Granted Patent US 10,376,525
Granted Patent B2
US 10,376,525 · App. 15/011,999 · Granted Aug 13, 2019

Treprostinil administration by inhalation

Inventors: Horst Olschewski (Graz, AT); Robert Roscigno (Chapel Hill, NC); Lewis J. Rubin (LaJolla, CA); Thomas Schmehl (Giessen, DE); Werner Seeger (Giessen, DE); Carl Sterritt (Weybridge, GB); Robert Voswinckel (Giessen, DE)
Assignee: United Therapeutics Corporation
A61K31/557A61K9/008A61K9/0078A61K31/192
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,376,525
App. No.
15/011,999
Granted
Aug 13, 2019
Kind
B2
Abstract

Treprostinil can be administered using a metered dose inhaler. Such administration provides a greater degree of autonomy to patients. Also disclosed are kits that include a metered dose inhaler containing a pharmaceutical formulation containing treprostinil.

Claims (4)

1. A method of treating pulmonary hypertension comprising: administering by inhalation to a human suffering from pulmonary hypertension a therapeutically effective single event dose of a formulation comprising from 200 to 1000 μg/ml of treprostinil or a pharmaceutically acceptable salt thereof with a pulsed ultrasonic nebulizer that aerosolizes a fixed amount of treprostinil or a pharmaceutically acceptable salt thereof per pulse, said pulsed ultrasonic nebulizer comprising an opto-acoustical trigger that allows said human to synchronize each breath to each pulse, said therapeutically effective single event dose comprising from 15 μg to 90 μg of treprostinil or a pharmaceutically acceptable salt thereof delivered in 3 to 18 breaths, wherein the fixed amount of treprostinil or its pharmaceutically acceptable salt for each breath inhaled by the human comprises at least 5 μg of treprostinil or its pharmaceutically acceptable salt.

2. The method of claim 1 , wherein the single event dose produces a peak plasma concentration of treprostinil below 1.74 ng/ml about 10-15 minutes after the single event dose.

3. The method of claim 1 , wherein the formulation comprises 600 μg/ml of the treprostinil or its pharmaceutically acceptable salt thereof.

4. The method of claim 1 , wherein the single event dose is not repeated for a period of at least 3 hours.

Continuity (5)
Division 13469854 · May 11, 2012
Division 12591200 · Nov 12, 2009
Continuation 11748205 · May 14, 2007
Provisional Application 60800016 · May 15, 2006
Related Publication 20160143868A1 · May 26, 2016
Cited By (5)
US 12,390,475 US 12,508,376 US 12,697,315 US 12,734,143 US 12,740,954